Full-Time

Scientist 2/Senior Scientist 1

In-Vivo Pharmacology

Updated on 7/21/2026

Antares Therapeutics

Antares Therapeutics

51-200 employees

Develops precision oncology therapeutics and pipelines

Compensation Overview

$145k - $185k/yr

Boston, MA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Pharmacology
Data Analysis

Get referred to Antares Therapeutics

Find people who can refer or advise you

Requirements
  • PhD. in Immunology, Pharmacology, or a related discipline
  • 3+ years of industry experience with expertise in mouse models of autoimmune disease
  • Strong foundation in translational immunology, including experience designing and executing in vivo studies
  • Experience in biomarker assay development, cytokine profiling, immune-cell characterization, scRNAseq, flow cytometry, and preparing human biospecimen samples
  • Proven ability to analyze complex biological data and communicate findings clearly
  • Strong organizational skills and attention to detail
  • Excellent interpersonal and communication skills with a collaborative mindset
  • Ability to manage multiple priorities and deliver high-quality results in a fast-paced environment
  • Track record of scientific achievement, including publications or impactful project contributions
Responsibilities
  • Design, plan, and execute in vivo pharmacology studies in mouse models of autoimmune disease
  • Analyze, interpret, and present complex datasets to multidisciplinary project teams and senior leadership
  • Collaborate cross-functionally with biology, medicinal chemistry, and DMPK teams to inform study design and data interpretation
  • Maintain accurate, detailed, and timely experimental records in electronic lab notebooks (ELN)
  • Contribute to study reports, regulatory documentation, and scientific publications as needed
Desired Qualifications
  • None

Antares Therapeutics focuses on developing precision oncology medicines. It advances targeted cancer therapies by leveraging Scorpion Therapeutics’ discovery platform acquired by Lilly, using its validated pipeline and leadership with deep oncology experience to guide research and development. The company works by identifying cancer-specific targets and creating therapies that act on those targets, followed by clinical validation and eventual commercialization in advanced cancer indications. Its differentiation comes from access to Scorpion’s discovery capabilities, the support and resources of Lilly, and a leadership team with experience in oncology and life sciences, enabling a science-driven approach to push the boundaries of precision medicine. Antares aims to shape the future of precision oncology by delivering transformative treatments that can improve outcomes for cancer patients.

Company Size

51-200

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$282M

Headquarters

Boston, Massachusetts

Founded

2025

Get referred to Antares Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Novartis paid $105M upfront for a collaboration worth up to $1.9B in milestones.
  • Antares' lead precision oncology program enters clinical trials in 2026.
  • Existing partnerships with AstraZeneca and Pierre Fabre validate Antares' discovery platform.

What critics are saying

  • Novartis may opt out within 12–18 months, leaving Antares with stranded R&D costs.
  • Lead program delays beyond 2026 due to toxicology or selectivity failures appear likely.
  • Failure to secure $150M–$250M Series B by Q1 2027 could force pipeline scale-down.

What makes Antares Therapeutics unique

  • Antares uses a proprietary covalent drug discovery engine targeting undruggable transcription factors.
  • The company spun out from Scorpion Therapeutics, leveraging a validated small molecule pipeline.
  • Antares combines mass spectrometry, chemical proteomics, and pocket-finding for precision oncology.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

6%

2 year growth

8%
Antares Therapeutics
Jul 9th, 2026
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies

– Multi-target collaboration will leverage Antares’ proprietary discovery engine to generate highly selective small molecule medicines against historically undruggable oncology targets –

Business Wire
Jun 11th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...

Pipeline Review
Jun 10th, 2025
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

BOSTON, MA, USA I June 10, 2025 I Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing.